The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori

Journal of Digestive Diseases

Volumn 8, Issue 4, 2007, Pages 211-215

  Uygun, Ahmet ^a   Kadayifci, Abdurrahman ^d   Safali, Mukerrem ^b   Ilgan, Seyfettin ^c   Bagci, Sait ^a  

^a Department of Gastroenterology ^*  (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

^c GULHANE SCHOOL OF MEDICINE   (Turkey)

^d GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

Bismuth subsalicylate; Clarithromycin; Eradication; Helicobacter pylori; Resistance

Indexed keywords

2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; AMOXICILLIN; ANTIINFECTIVE AGENT; ANTIULCER AGENT; BISMUTH; CLARITHROMYCIN; LANSOPRAZOLE; METRONIDAZOLE; TETRACYCLINE;

ADULT; AGED; ARTICLE; BREATH ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DYSPEPSIA; GASTROSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BISMUTH; BREATH TESTS; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; DYSPEPSIA; GASTROSCOPY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; METRONIDAZOLE; MIDDLE AGED; SINGLE-BLIND METHOD; STATISTICS, NONPARAMETRIC; TETRACYCLINE; TREATMENT OUTCOME;

EID: 85047688500     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2007.00308.x     Document Type: Article

References (29)

1. Malfertheiner P, Megraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 6: 167-80.
2. Malfertheiner P, Megraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection - The Maastricht III Consensus Report. Gut 2007 Jan 17; [Epub].
3. Bochenek WJ, Peters S, Fraga PD et al. Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. Helicobacter 2003; 8: 626-42.
4. Palmas F, Pellicano R, Massimetti E, Berrutti M, Fagoonee S, Rizzetto M. Eradication of Helicobacter pylori infection with proton pump inhibitor-based triple therapy. A randomised study. Panminerva Med 2002; 44: 145-7.
5. Sivri B, Simsek I, Hulagu S et al. The efficacy, safety and tolerability of pantoprazole-based one-week triple therapy in H. pylori eradication and duodenal ulcer healing. Curr Med Res Opin 2004; 20: 1301-7.
6. Kadayifci A, Buyukhatipoglu H, Savas MC, Simsek I. Eradication of Helicobecter pylori with triple therapy: an epidemiologic anaysis of trends in Turkey over 10 years. Clin Ther 2006; 11: 1960-6.
7. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161-81.
8. Canadian Helicobacter Study Group Consensus Conference. Update on the approach to Helicobacter pylori infection in children and adolescents - an evidence-based evaluation. Can J Gastroenterol 2005; 19: 399-408.
9. Mones J, Gisbert JP, Borda F, Dominguez-Munoz E, Grupo Conferencia Espanola de Consenso Sobre Helicobacter Pylori. Indications, diagnostic tests and Helicobacter pylori eradication therapy. Recommendations by the 2nd Spanish Consensus Conference. Rev Esp Enferm Dig 2005; 97: 348-74.
10. Ulmer HJ, Beckerling A, Gatz G. Recent use of proton pump inhibitor-based triple therapies for the eradication of H. pylori: a broad data review. Helicobacter 2003; 8: 95-104.
11. Megraud F, Lehn N, Lind T et al. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother 1999; 43: 2747-52.
12. Malfertheiner P, Bayerdorffer E, Diete U et al. The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther 1999; 13: 703-12.
13. Zanten SJ, Bradette M, Farley A et al. The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Aliment Pharmacol Ther 1999; 13: 289-95.
14. Perez Aldana L, Kato M, Nakagawa S et al. The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter 2002; 7: 306-9.
15. Toracchio S, Marzio L. Primary and secondary antibiotic resistance of Helicobacter pylori strains isolated in central Italy during the years 1998-2002. Dig Liver Dis 2003; 35: 541-5.
16. Simsek H, Balaban YH, Gunes DD, Hascelik G, Ozarslan E, Tatar G. Alarming clarithromycin resistance of Helicobacter pylori in Turkish population. Helicobacter 2005; 10: 360-1.
17. Can F, Demirbilek M, Selcuk H, Arslan H, Boyacioglu S. Clarithromycin resistance of Helicobacter pylori strains isolated from antral biopsy specimens. Mikrobiyol Bul 2004; 38: 349-3.
18. Neri M, Milano A, Laterza F et al. Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments. Aliment Pharmacol Ther 2003; 18: 821-7.
19. Boixeda D, Martin De Argila C, Bermejo F, Lopez Sanroman A, Hernandez Ranz F, Garcia Plaza A. A. Seven-day proton pump inhibitor, amoxicillin and clarithromycin triple therapy: factors that influence Helicobacter pylori eradications success. Rev Esp Enferm Dig 2003; 95: 202-9.
20. Malekzadeh R, Merat S, Derakhshan MH et al. Low Helicobacter pylori eradication rates with 4- and 7-day regimens in an Iranian population. J Gastroenterol Hepatol 2003; 18: 13-17.
21. Kawabata H, Habu Y, Tomioka H et al. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. Aliment Pharmacol Ther 2003; 17: 259-64.
22. McMahon BJ, Hennessy TW, Bensler JM et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 2003; 139: 463-9.
23. Kadayifci A, Simsek H, Tatar G. The efficiency of omeprazole and dual antibiotic treatment schemes for H. pylori eradication. Turk J Gastroenterol 1996; 7: 228-32.
24. Uygun A, Ates Y, Erdil A et al. Efficacy of omeprazole plus two antimicrobials for the eradication of Helicobacter pylori in a Turkish population. Clin Ther 1999; 21: 1539-48.
25. Uygun A, Kadayifci A, Yesilova Z et al. Recent success of pantoprazole-or lansoprazole-based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori. Turk J Gastroenterol 2004; 15: 219-24.
26. Lambert JR, Midolo P. The actions of bismuth in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1997; 11 (Suppl.) (1): 27-33.
27. Chiba N. Effects of in vitro antibiotic resistance on treatment: bismuth-containing regimens. Can J Gastroenterol 2000; 14: 885-9.
28. de Boer WA. Bismuth triple therapy: still a very important drug regimen for curing Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1999; 11: 697-700.
29. Vilaichone RK, Mahachai V, Graham DY. Helicobacter pylori diagnosis and management. Gastroenterol Clin North Am 2006; 35: 229-47.